Figure 3 | Scientific Reports

Figure 3

From: Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Figure 3

Effect of adding daratumumab to backbone anti-myeloma regimens on the risk of death of disease progression in (A) newly-diagnosed multiple myeloma with high cytogenetic risk, (B) newly-diagnosed multiple myeloma with standard cytogenetic risk, (C) relapsed/refractory multiple myeloma with high cytogenetic risk, and (D) relapsed/refractory multiple myeloma with standard cytogenetic risk.

Back to article page